Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic ...

Coherus BioSciences Inc. (Nasdaq: CHRS) of Redwood City, California, completed the potential half-billion-dollar sale of its biosimilar anemia drug for cancer chemotherapy patients; Emeryville ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

In an ever-expanding field, firms are racing to attract new talent – just as a major shortage of stockbrokers looms. 2025 has been a rocky year so far for equity investors, but how you respond ...

The image, based on a 1984 photo of Jordan taken for a marketing campaign, has since become one of the most recognizable logos in sports apparel. Nike reported $5 billion in revenue from the ...

Coherus, meanwhile, says Yusimry is being offered at an 85% discount to the brand, at $995 for a box of two autoinjectors, which is equivalent to around $13,000 per year versus $85,000 for Humira.

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in biosimilar medicines and ...